New Strategies in the Development of Antidepressants: Towards the Modulation of Neuroplasticity Pathways
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Over the past five decades, the pharmacological treatment of depression has been based on the pathophysiological hypothesis of a deficiency in monoamines, mainly serotonin and noradrenaline. Antidepressant prescribed today, all of them designed to enhance central monoaminergic tone, present several important limitations, including a 2-5 weeks response lag and also a limited clinical efficacy. As it is increasingly evident that the abnormalities associated to depression go beyond monoamines, the development of better antidepressants will depend on the identification and understanding of new cellular targets. In this regard, much evidence supports a role for cellular and molecular mechanisms of neuroplasticity, including neurotrophic inputs, in mood disorders, in parallel with the biological features associated to stress conditions. In order to illustrate the possible relevance of neuroplasticity-related pathways for the therapy of depressive states, we here review the biological evidence supporting some therapeutic strategies in a very initial phase of development (modulation of the Wnt/GSK-3β/β-catenin pathway, potentiation of endocannabinoid activity, agonism of 5-HT(4) receptors), which involve modulation of downstream mechanisms and neuroplasticity circuits. These strategies also show the existence of mixed mechanisms of action, constituting a nexus between the "classic" aminergic theory and the "new" neuroplasticity hypothesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Biochemistry of Affective Disorders
Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230 · cited 1×
“Over the past five decades, the pharmacological treatment of depression has been based on the monoaminergic hypothesis of the pathophysiology of this disease [129] [130].”
Background
Cited by
Pathogenesis of depression: Insights from human and rodent studies
Ménard, C., Hodes, G. E., & Russo, S. J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.053 · Cited by 593
Structural and synaptic plasticity in stress-related disorders
Christoffel, D. J., Golden, S. A., & Russo, S. J. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.044 · Cited by 334
Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression
Golden, S. A., Christoffel, D. J., Heshmati, M., Hodes, G. E., Magida, J., Davis, K., Cahill, M. E., Dias, C., Ribeiro, E., Ables, J. L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3090 · Cited by 322
Serotonin receptors involved in antidepressant effects
Artigas, F. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.006 · Cited by 311
The serotonergic system and cognitive function
Švob Štrac, D., Pivac, N., & Mück-Šeler, D. (2016) · Translational Neuroscience · doi:10.1515/tnsci-2016-0007 · Cited by 285
Metadata
- Authors
- Vidal, R., Pilar-Cuellar, F., dos Anjos, S., Linge, R., Treceno, B., Ines Vargas, V., Rodriguez-Gaztelumendi, A., Mostany, R., Castro, E., Diaz, A., M. Valdizan, E., & Pazos, A.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-02-01
- Volume
- 17
- Issue
- 5
- Pages
- 521-533
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2011189731
- Cited by
- 55
- References
- 1
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Strategies in the Development of Antidepressants: Towards the Modulation of Neuroplasticity Pathways. https://app.cochat.ai/papers/10.2174/138161211795164086
- The paper
- Vidal, R., Pilar-Cuellar, F., dos Anjos, S., Linge, R., Treceno, B., Ines Vargas, V., Rodriguez-Gaztelumendi, A., Mostany, R., Castro, E., Diaz, A., M. Valdizan, E., & Pazos, A. (2011). New Strategies in the Development of Antidepressants: Towards the Modulation of Neuroplasticity Pathways. Current Pharmaceutical Design. https://doi.org/10.2174/138161211795164086
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.